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Introduction
Th  e development of speciﬁ   c biological therapies has 
resulted in a remarkable improvement in the treatment 
of rheumatoid arthritis (RA) and also in the under-
standing of its complex pathogenesis. We better recog-
nize the multitude of cells and biological pathways in-
volved in the disease process. We have also become more 
aware of the individual variability in disease features and 
in patterns of response to therapy. A large array of new 
treatment opportunities is currently under development 
and soon will be available as new biological agents. While 
enjoying these fruits of research, rheumatologists face 
the challenge of deﬁ  ning the best therapeutic plan for 
patients who have failed classical disease-modifying 
antirheumatic drugs (DMARDs).
Remission is now a realistic therapeutic goal in 
every patient
It is certainly desirable that our patients feel better and 
have improved function and acute-phase reactants as 
measured by response criteria, but the remaining inﬂ  am-
matory activity (status) seems decisive: ‘It is good to feel 
better but it is better to feel good’ [1]. Aletaha and 
colleagues [2] have demonstrated, in a pooled analysis 
based on data from several clinical trials in RA involving 
anti-tumor necrosis factor (anti-TNF), that within the 
ACR50 (American College of Rheumatology 50% 
improve  ment criteria) and ACR70 responder groups, the 
most important determinant of progression is the ﬁ  nal 
disease state and not the relative degree of improvement. 
In fact, functional ability was best and radiographic 
progression was lowest in patients who had attained 
disease remission at 1 year compared with those who had 
attained only low or moderate disease activity. Further-
more, among patients attaining the same disease activity 
category, physical function and radiographic progression 
did not diﬀ  er signiﬁ  cantly by the level of response. Even 
with low disease activity, damage progresses and only 
sustained remission is capable of abrogating progression 
of joint destruction [3]. Moreover, optimal disease 
control is associated with less work disability [4], lower 
mortality rates [5-7], and better quality of life [8,9]. Even 
if low disease activity is achieved, work productivity, 
quality of life, and health states are still signiﬁ  cantly 
worse when compared with remission [9]. Remission 
used to be a ‘guiding utopia’ but now, thanks to biological 
therapy, is a very realistic therapeutic objective. Now that 
we have in our hands a variety of safe and eﬃ   cacious 
medications to achieve it, remission should be our goal in 
every patient with RA and we should try to achieve that 
goal as soon as possible [10].
Defi  ning remission
Remission, our elected goal, should be understood as a 
near-complete suppression of disease activity or an 
absence of discernable disease activity [11]. Which of the 
current deﬁ   nitions of remission should we adopt for 
practice and for evaluation of the eﬃ   cacy of diﬀ  erent 
treatment regimes? Remission deﬁ  nitions (Table 1) and 
their diﬀ  erences have been assessed and reviewed in detail 
[12-17]. As expected, the proportion of patients achieving 
remission is dependent on how it is deﬁ  ned [17].
Molenaar and colleagues [18] found that some patients 
in clinical remission, deﬁ  ned according to the modiﬁ  ed 
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21] or the disease activity score (DAS) criteria [20], still 
showed radiographic progression during a 2-year follow-
up, although to a lesser extent than patients having an 
exacer bation.  Th  ese ﬁ   ndings suggest that DAS/disease 
activity score with 28-joint assessment (DAS28) and ARA 
remission criteria may actually describe a low disease 
activity state rather than a true remission state [22]. In 
recent trials, DAS28 remission rates exceeded ACR70 
response rates [23-26], meaning that more patients 
achieved a state of DAS28 remission than the proportion 
of patients reach  ing a decrease of 70% or higher in tender 
and swollen joints. However, other reports have 
suggested that DAS remission is a more strict criterion 
for remission and that an ACR70 response should not be 
used as a surrogate for remission [27]. Th   is should not be 
surprising given that ACR20/ACR50/ACR70 is designed 
to measure improve  ment in disease activity, not to deﬁ  ne 
remission. Impor  tantly, some recent reports have 
suggested that the clinical disease activity index (CDAI) 
and simpliﬁ   ed disease activity index (SDAI) [28] may 
represent remis  sion criteria that are more stringent than 
those by the DAS/DAS28 and the modiﬁ  ed  ARA 
response criteria because the latter allow for signiﬁ  cant 
residual disease activity [27,29]. Consequently, smaller 
proportions of patients may be classiﬁ  ed as in remission 
by SDAI and CDAI criteria than by DAS/DAS28 and 
modiﬁ  ed ARA criteria, and this also has an impact on the 
percentage of patients showing radiological progression 
and on patients’ mean health assessment questionnaire 
(HAQ) scores [16,30,31]. One limitation of all of these 
remission deﬁ   nitions (ARA, DAS/DAS28, and CDAI/
SDAI) is that they omit the eﬀ  ects of RA on functional 
disability and structural joint damage [28].
Owing to these limitations in the deﬁ  nitions of remis-
sion and recognizing its importance as a crucial goal in 
current management of RA, ACR and the European 
League Against Rheumatism (EULAR) set up a task force 
to redeﬁ  ne the concept. Th   e main conclusions from the 
ﬁ  rst meeting are that the new remission deﬁ  nition should 
be strict, based on no or very low disease activity, and 
should be validated against long-term outcomes, speci-
ﬁ   cally physical function and radiographic progres  sion 
[14]. Th   ose in remission should have a stable level of joint 
damage over time and should have less deterioration or 
more improvement in functional status over time 
(remission deﬁ   nition should have predictive validity) 
[14].
It is our opinion that, while we await this new 
deﬁ  nition, the practicing rheumatologist should do the 
following:
1. Choose persistent remission as the primary goal for 
every patient with RA.
2.  Always measure disease activity, using any of the 
available tools (DAS/DAS28, CDAI/SDAI) to guide 
therapy toward remission (benchmarking).
3. If remission has been achieved, be critical about it. 
Check whether the patient fulﬁ  lls available remission 
criteria and if the patient does, ask yourself whether 
that is ‘true remission’ (for example, a very low 
erythro  cyte sedimentation rate [ESR] or very low/
absent number of tender joints may be leading you to 
categorize the patient in a ‘false state of remission’). 
Also, be critical about other disease states (for example, 
a patient with chronically elevated acute-phase 
reactants not related to RA or a patient with RA and 
ﬁ   bromyalgia may never fulﬁ   ll current deﬁ  nitions  of 
remission but may nonetheless be in ‘true remission’).
4. If the patient is not in ‘true’ and persistent remission, 
continue the search for that goal.
Th  e remainder of this paper will discuss data on DAS/
DAS28 remission and ACR70 response rates.
Table 1. Remission criteria
Criteria Components/Formula  Cut-off  s
ARA [19] and modifi  ed  No fatigue (used only for ARA, not for modifi  ed ARA criteria)  5/6 for ARA criteria and 4/5 for modifi  ed
ARA [20,21]  No joint pain by history  ARA; 2 months required
  No joint tenderness or pain on motion
  No soft tissue swelling in joints or tendon sheaths
 Morning  stiff  ness for not more than 15 minutes
  ESR of less than 30 mm/hour in women and less than 20 mm/hour in men
DAS [20]  [0.54 × √(Ritchie)] + [0.065 × SJC44] + [0.33 × ln (ESR)] + [0.0072 × GH (mm)]  Less than 1.6
DAS28 [21]  [0.56 × √(TJC28)] + [0.28 × √(SJC28)] + [0.70 × ln (ESR)] + [0.014 × GH (mm)]  Less than 2.6 (less than 2.4 also proposed) [28]
SDAI [28]  SJC28 + TJC28 + PGA (cm) + EGA (cm) + CRP (mg/dL)  Not more than 3.3
CDAI [54]  SJC 28 + TJC28 + PGA (cm) + EGA (cm)  Not more than 2.8
ARA, American Rheumatism Association; CDAI, clinical disease activity index; CRP, C-reactive protein; DAS, disease activity score; DAS28, disease activity score with 
28-joint assessment; EGA, evaluator global assessment of disease activity; ESR, erythrocyte sedimentation rate; GH, global health by visual analogue scale; ln, natural 
logarithm; PGA, patient global assessment of disease activity; Ritchie, Ritchie articular index; SDAI, simplifi  ed disease activity index; SJC28, 28 swollen joint count; 
SJC44, 44 swollen joint count; TJC28, 28 tender joint count.
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remission?
It can be expected that 10% to 30% of unselected patients 
with RA will achieve remission (natural history data) 
[32]. According to current guidelines in most countries, 
biologics should be considered if patients do not respond 
to traditional DMARDs, including methotrexate (MTX), 
during the ﬁ   rst few months of treatment [33]. Most 
clinicians who now face a traditional DMARD failure en-
counter the problem of selecting among currently 
approved biological therapies (adalimumab, etanercept, 
inﬂ  iximab, abatacept, rituximab, tocilizumab, certolizu-
mab pegol, golimumab, and anakinra).
According to the current methodological paradigm, no 
formal judgment on the relative merits of drugs can be 
made in the absence of head-to-head trials. Th  e only 
published head-to-head trial with biologics had three 
arms: abatacept, inﬂ   iximab, and placebo. Th  e relative 
eﬃ   cacies of the biologics were similar at 6 months, with 
signiﬁ  cant  diﬀ   erences favoring abatacept at 1 year in 
DAS28, good EULAR response, low disease activity, and 
health-related quality of life [34]. One additional head-to-
head trial recently started recruiting patients to be 
randomly assigned to tocilizumab or adalimumab and we 
are looking forward to the results [35]. Other trials of this 
kind are lacking and would be welcome. While waiting 
for more information from clinical trials, the clinician 
still needs to make a decision. How?
Looking independently at individual trials is not very 
informative. ACR20, ACR50, and ACR70 response rates 
in randomized trials are not very diﬀ  erent  between 
diﬀ  erent drugs, and a crude analysis is not elucidative. 
Several aspects, including diﬀ  erences in placebo response 
rates, trial designs, inclusion and exclusion criteria, and 
safety proﬁ   le, should be taken into account. In the 
absence of any evidence of relevant diﬀ  erences between 
biologics, the clinician may leave the choice to the 
patient, allowing convenience of administration, access to 
medication, and safety concerns to serve as guides.
Indirect comparisons produced through formal statis-
tical methodologies have been proposed in an attempt to 
help clinicians make a choice. We could ﬁ  nd three such 
analyses. Singh and colleagues [36] systematically reviewed 
the existing updated Cochrane systematic reviews of six 
biologic DMARDs for RA (abatacept, adalimumab, 
etanercept, inﬂ   iximab, rituximab, and anakinra). Th  is 
review included biologic DMARDs alone used in 
standard approved doses or in combination with other 
biologic/traditional DMARDs compared with placebo 
alone or with placebo plus biologic/traditional DMARDs. 
Th   e authors anticipated that the observed ‘control event 
rate’ (that is, the placebo eﬀ  ect) and the trial duration 
would be important eﬀ  ect  modiﬁ   ers and adjusted for 
these factors in the analysis (Table 2). Following this 
method ology,  ﬁ   ve biologics (abatacept, adalimumab, 
etaner cept,  inﬂ  iximab, and rituximab) showed signiﬁ  cant 
superiority to placebo but did not diﬀ  er  among 
themselves. A summary of statistics is presented for the 
main eﬃ   cacy outcome of the study, ACR50, as a global 
‘number needed to treat’ (NNT) to beneﬁ  t from each 
drug: abatacept NNT = 5 (95% conﬁ  dence interval [CI] 3 
to 10), adalimumab NNT = 4 (95% CI 3 to 6), etanercept 
NNT = 3 (95% CI 3 to 5), inﬂ  iximab NNT = 5 (95% CI 3 
to 18), and rituximab NNT = 4 (95% CI 3 to 8).
Bergman and colleagues [37] conducted a mixed-
treatment comparison of biologic DMARD eﬃ   cacy  at 
24  weeks, among traditional DMARD inadequate res-
pon  ders, in order to make treatment-to-treatment com-
pari sons.  Th  is analysis included data from tocilizumab 
trials, and besides establishing comparisons with placebo, 
the authors further estimated the eﬃ   cacy of tocilizumab 
in comparison with other biologics (anti-TNF being 
considered a block). A signiﬁ  cant diﬀ  erence was found 
between all biologic DMARDs and placebo in the three 
outcomes (ACR20, ACR50, and ACR70) (Table 3). Relative 
risks (RRs) compared with placebo were similar for 
ACR20, but for ACR50 and especially ACR70, tocilizumab 
had a higher probability of response than other biologic 
DMARDs. Tocilizumab had an eﬃ   cacy similar to that of 
other biologic DMARDs for ACR20 and ACR50 responses, 
but a signiﬁ  cantly higher ACR70 response compared with 
TNF-α inhibitors (RR 1.8, 97.5% CI 1.2 to 2.6) and 
abatacept (RR 2.0, 97.5% CI 1.3 to 3.1) (Table 3).
Gartlehner and colleagues [38] also performed a meta-
analysis and indirect comparisons between biologics in 
populations that had residual disease activity despite 
MTX treatment (that is, excluded MTX-naïve patients), 
but only the three anti-TNF treatments were included, 
and no signiﬁ  cant diﬀ  erences were found.
Th  ese comparisons lack suﬃ     cient data on remission 
because not all of the randomized controlled trials 
(RCTs) provide that information. Consequently, the most 
ambitious outcome one can derive from these studies is 
ACR70. Overall, the abovementioned studies suggest that 
the eﬃ   cacies  of  diﬀ   erent biologics regarding this 
endpoint are very similar. Th   e only exception seems to be 
a higher response rate, for ACR70, for tocilizumab (anti-
TNFs being considered together). Notably, however, 
whether or not a patient will experience an ACR70 
response is dependent not only on the eﬃ   cacy of the 
intervention but also on the baseline level of disease 
activity, and this duality makes ACR70 responses tricky 
for indirect comparisons.
With respect to radiographic progression, a comparison 
between biologics is more diﬃ     cult because of the 
heterogeneity of the methodology applied, but in general, 
all biologic drugs have shown the potential of successfully 
inhibiting structural damage progression.
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guish biologics on the basis of published evidence for 
eﬃ   cacy? Th   ese indirect analyses look promising and are 
very appealing to the reader but actually have a number 
of methodological drawbacks, and therefore ﬁ  ndings 
need to be interpreted with caution. What indirect com-
pari  sons actually do is adjust for the placebo response 
across trials under the assumption that the placebo 
response is a generic reﬂ  ection of the characteristics of 
the study population without active intervention. A 
second assumption is that there is a clear and linear 
relationship between the placebo response and the 
response in the active treatment group. In the 2010 
EULAR recommendations for the management of RA 
[39], the expert team deliberately refrained from includ-
ing these indirect comparisons. Having reviewed the 
literature systematically, the authors concluded that it 
was impossible to prioritize the several biologics.
Can biologics be distinguished on the basis of 
safety?
Singh and colleagues [36] evaluated withdrawals due to 
adverse events and concluded that, compared with 
patients receiving placebo, those receiving adalimumab 
and inﬂ  iximab were at signiﬁ  cantly higher risk of with-
drawals due to adverse events (odds ratio [OR] ranging 
from 1.54 to 2.21). Patients receiving abatacept, etaner-
cept, and rituximab did not diﬀ  er signiﬁ  cantly from those 
receiving placebo in this aspect. Indirect comparisons 
revealed that adalimumab was more likely to lead to 
withdrawals compared with etanercept (OR 1.89, 95% CI 
1.18 to 3.04) and etanercept was less likely than inﬂ  iximab 
(OR 0.37, 95% CI 0.19 to 0.70). Th  e results were also 
translated into an absolute value, in this case number 
needed to harm (NNH): adalimumab NNH = 39 (95% CI 
19 to 162) and inﬂ  iximab NNH = 18 (95% CI 8 to 72). 
Th  is comparison, unfortunately, does not include tocili-
zu  mab, a drug that was shown to have a rate of with-
drawals due to adverse events of 5.8 per 100 patient-
years, driven mainly by elevated liver enzyme levels, 
infections, and benign and malignant neoplasms [40]. 
Additionally, there seem to be diﬀ  erences in the risk of 
tuberculosis (TB) among diﬀ   erent biologics, and this 
might contribute to the selection of the biological agent, 
Table 2. Biologics combined 3-, 6-, and 12-month outcome 
data (ACR20/ACR50/ACR70), adjusted for control event 
rate
    Combined 3-, 6-, and 12-month outcome data: 
    relative risk (95% confi  dence interval) versus placebo
ACR20
  Abatacept  1.72 (1.38 to 2.15)
  Adalimumab  2.08 (1.71 to 2.52)
  Etanercept  2.09 (1.58 to 2.77)
  Infl  iximab  1.71 (1.23 to 2.38)
  Rituximab  1.93 (1.40 to 2.56)
ACR50
  Abatacept  2.29 (1.62 to 3.24)
  Adalimumab  3.05 (2.29 to 4.07)
  Etanercept  2.93 (1.94 to 4.44)
  Infl  iximab  2.16 (1.36 to 3.41)
  Rituximab  2.92 (1.76 to 4.83)
ACR70
  Abatacept  3.40 (2.10 to 4.94)
  Adalimumab  4.01 (2.71 to 5.92)
  Etanercept  3.02 (1.94 to 4.70)
  Infl  iximab  2.49 (1.47 to 4.24)
  Rituximab  4.48 (2.12 to 9.45)
Data extracted from Singh and colleagues [36]. ACR20, American College 
of Rheumatology 20% improvement criteria; ACR50, American College 
of Rheumatology 50% improvement criteria; ACR70, American College of 
Rheumatology 70% improvement criteria.
Table 3. Relative treatment eff  ect for ACR20/ACR50/ACR70 
responses in DMARD-IR patients
     Tocilizumab
     versus
   Biologic  DMARD  alternative 
   versus  biologic 
   placebo:  DMARDs:
   relative  relative
    risk (97.5% CI)  risk (97.5% CI)
ACR20 (random-eff  ects model)a
  Tocilizumab  2.1 (1.6 to 2.5)  1
  TNF-α inhibitors  2.0 (1.7 to 2.3)  1.1 (0.8 to 1.3)
  Abatacept  1.9 (1.4 to 2.3)  1.1 (0.8 to 1.6)
  Rituximab  1.9 (1.3 to 2.5)  1.1 (0.8 to 1.7)
ACR50 (random-eff  ects model)a
  Tocilizumab  3.6 (2.5 to 5.0)  1
  TNF-α inhibitors  3.2 (2.5 to 4.3)  1.1 (0.7 to 1.6)
  Abatacept  2.7 (1.7 to 4.0)  1.3 (0.8 to 2.3)
  Rituximab  2.9 (1.5 to 4.9)  1.2 (0.7 to 2.5)
ACR70 (fi  xed-eff  ects model)a
  Tocilizumab  6.8 (4.9 to 9.4)  1
  TNF-α inhibitors  3.8 (3.1 to 4.8)  1.8 (1.2 to 2.6)
  Abatacept  3.4 (2.5 to 4.8)  2.0 (1.3 to 3.1)
  Rituximab  4.3 (2.2 to 8.9)  1.6 (0.7 to 3.3)
Data extracted from Bergman and colleagues [37]. aOnly the most appropriate 
estimates, according to the authors, are presented, namely random-eff  ects 
estimated for ACR20 and ACR50 and fi  xed-eff  ects estimates for ACR70 
responses. ACR20, American College of Rheumatology 20% improvement 
criteria; ACR50, American College of Rheumatology 50% improvement criteria; 
ACR70, American College of Rheumatology 70% improvement criteria; CI, 
confi  dence interval; DMARD, disease-modifying antirheumatic drug; DMARD-
IR, disease-modifying antirheumatic drug-inadequate response; TNF-α, tumor 
necrosis factor-alpha.
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Monoclonal antibodies (that is, inﬂ   iximab and adali-
mumab) are known for a higher risk of TB compared 
with soluble TNF receptor therapy (that is, etanercept) 
[41,42]. Minimal data on TB risk in patients treated with 
non-TNF biological therapies exist, but to date, this risk 
seems to be limited [42]. Overall, the safety proﬁ  le of 
biologics in long-term registries has been very satis-
factory, and it is accepted that diﬀ  erences in safety proﬁ  le 
would not warrant a major impact in the selection of 
medication, given the potential beneﬁ  ts at stake [43].
In summary, the clinician is still faced with considerable 
diﬃ   culty in performing an evidence-based selection of 
the best possible biologic to add to MTX. At the moment, 
little evidence of any signiﬁ  cant diﬀ  erence between the 
biologics exists. Th   e clinician will weigh beneﬁ  ts against 
risks speciﬁ  c to each biologic in addition to considering 
the common adverse events of all of the biologics [44]. 
Examples of speciﬁ   c adverse events might be neutro-
penia, increases in total cholesterol, lipoproteins, and 
triglycerides associated with tocilizumab [26,40]; or 
progressive multifocal leukoencephalopathy associated 
with rituximab [45]. Of course, such diﬃ   culties would be 
overcome if the individual response to each biologic 
could be reliably predicted. Th   is would allow us to hope 
that we can do better than average.
Can response to individual therapeutic agents be 
predicted?
Th   e fact that biologics are quite similar in terms of res-
ponse rate at the group level does not preclude them 
from being completely diﬀ  erent at the individual level. 
Evaluation of RCTs is based on averages, and surely the 
majority of patients will not behave like the average; it 
may even happen that not a single one will. In a 
hypothetical scenario in which 20% of the population 
responds to one out of ﬁ  ve diﬀ  erent medications but to 
none of the others, all ﬁ  ve medications would have the 
same response rate at the group level (20%) and be 
considered indistinguishable. However, this conclusion 
would be wrong to each and every patient!
In fact, diﬀ  erent agents may be eﬀ  ective in diﬀ  erent 
people, and if this concept is applied to the RA 
therapeutic arsenal, there might be such a thing as a 
disease primarily responsive to MTX, an anti-TNF 
biologic, an anti-interleukin-6 (IL-6) biologic, and so on. 
Diﬀ   erent ‘sensitivity’ to diﬀ   erent targeted agents is 
actually to be expected in a complex multifactorial 
disease like RA, as a function of the relative dominance 
of one biological pathway over the others in a particular 
individual, depending on environmental and genetic 
factors. It is conceivable that the dominant pathogenic 
mechanisms (and therefore drug responses) may even 
vary within a patient in the course of the disease. Th  is 
concept cannot be proven at the moment, because the 
data available have been driven essentially by historical 
opportunity: anti-TNF were the ﬁ  rst to become available 
and for that reason they became ﬁ   rst line, and the 
alternatives used upon their failure. Moreover, current 
methodological wisdom is based on average responses 
and subgroup analysis is precluded.
Th   e optimal selection among these medications for an 
individual patient would require that we be able to 
identify the subset of patients who would respond better 
to each drug. In this case, initial treatment could be 
tailored to the individual and we could aim at shortening 
the time to onset of eﬀ  ective treatment, improving the 
cost-beneﬁ  t and risk-beneﬁ  t ratios of these agents, and 
eventually achieving 100% response rate with minimal 
toxicity.
Several demographic and clinical characteristics as well 
as serological biomarkers have been studied as predictors 
of treatment response. Large-scale genetic and proteome 
studies are now available and have led to the study of 
genetic polymorphisms (pharmacogenetics) and screen-
ing of large amounts of gene transcripts (transcriptomic 
analysis of pharmacogenomics) and proteins (proteomic 
analysis of pharmacogenomics) as candidate biomarkers. 
Several polymorphisms in genes of MTX transporters 
and the folic acid and adenosine pathways have been 
studied for MTX response, whereas for anti-TNF-α 
response, major histocompatibility complex and Fc-
recep  tor polymorphisms have been the main candidates.
So far, however, no clear-cut relationships between 
demo  graphic, clinical, biochemical, or genetic factors 
and RA response to biological therapy have been 
established [46,47]. Th   is may reﬂ  ect diﬀ  erences in study 
design, diﬃ   culty in controlling for confounders (such as 
ethnicity, age, disease duration, concomitant therapy, and 
smoking), or simply the inadequacy of proposed markers 
[47-49]. It is likely that sensitivity to therapies depends on 
a conjunction of factors whose study will require complex 
models combining genetic and non-genetic factors, as 
proposed by Wessels and colleagues [50] for predicting 
the eﬃ   cacy of MTX monotherapy.
In regard to response to anti-TNF agents, most of the 
studies performed to date have been small, under-
powered, and restricted to the analysis of single candidate 
genes. Th   e only replicated and validated genetic predictor 
of anti-TNF response is the 308GA single-nucleotide 
polymorphism in the TNF promoter region, but the 
amount of variation in response accounted for by this 
marker is probably modest and was questioned in a 
recent meta-analysis [51]. It is still unknown whether 
variation in treatment response is determined by several 
genes that each have a small eﬀ   ect size or by small 
numbers of genes with large eﬀ  ect sizes. Authors agree 
on the need for a large-scale, non-hypothesis-driven 
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response [47]. In summary, at present, there is no robust 
biomarker to allow the prediction of responsiveness of 
individual patients to each biological agent.
Conclusions
Now what? How should the practicing rheumatologist 
select biologics upon failure of MTX or classical DMARD 
combination? Let us summarize the problem. Th  e need 
for early introduction and rapid escalation of therapy in a 
response-driven strategy leaves little room for doubt. 
Th   ere is also little doubt that the physician should treat to 
target and that the elected target should be remission, 
unless this is proven impossible. Th   e number of biologics 
available and their eﬃ   cacy make this target potentially 
attainable for every patient. At the moment, there is no 
way to predict individual response to each of these 
agents.
How should the clinician proceed?
In our view, the best strategy in the absence of the ability 
to predict response to speciﬁ  c biologics consists of trial 
and error and is based on three main principles: (a) start 
with an eﬀ   ective agent, (b) move to another eﬀ  ective 
agent unless persistent remission is achieved with 
acceptable toxicity, and (c) consider going back to the 
most eﬀ  ective agent if none of the biologic DMARDs 
results in remission. We could name this strategy ‘cycling 
for remission’. Th  is process could develop at a relatively 
fast pace, thus avoiding the risk of leaving a patient for 
too long with ineﬀ   ective medication. Aletaha and 
colleagues [52] showed that a patient’s response to 
treatment during the ﬁ  rst 3 months of biological therapy 
determined the level of disease activity at 1 year. So, quite 
soon after therapy has been started, the clinician can 
assess the eﬃ   cacy of each biological agent in controlling 
disease activity at 1 year.
Where should the clinician start?
With the currently available evidence, the order in which 
available biological agents should be used cannot be 
established on evidence-based grounds. Th   is view is also 
adopted by the 2010 EULAR recommendations for the 
management of RA; the authors refrain from taking a 
position with regard to the preferred biologic drug [39]. 
We fully agree with this position in general. It will 
obviously require adaptation according to characteristics 
and preferences of individual patients, safety concerns, 
access to medications, and local policies. Etanercept and 
abatacept may be considered for a higher order of priority 
if the safety proﬁ  le is given a higher importance, and the 
opposite may happen with adalimumab and inﬂ  iximab. 
Th   e priority of rituximab may be inﬂ  uenced by rheuma-
toid factor status since patients with positive rheumatoid 
factor seem to be the best candidates for rituximab [53]. 
Approval status of a drug (that is, as ﬁ  rst or second line) 
also inﬂ  uences treatment selection. Th  e individual risk 
proﬁ  le of a patient should also be taken into account and 
balanced with an individual’s relative and absolute risk of 
an adverse event with each biological agent. In many 
cases, the lack of these data may lead the clinician to 
make the best clinical judgment. TB prevalence and risk 
shall also be considered, and when the risk of TB is high, 
non-TNF inhibitors or etanercept may be preferred over 
monoclonal antibodies.
Th   e EULAR 2010 recommendations [39] also state that 
it is ‘current practice’ to prescribe a TNF blocker ﬁ  rst, 
implying that the newer biologicals (rituximab, abatacept, 
and tocilizumab) come thereafter. Th  e accumulated ex-
peri  ence with anti-TNFs may be invoked to support their 
use as ﬁ  rst line. However, it could be argued that more 
recent biologics have far more controlled data than the 
original anti-TNFs. Furthermore, the argument of greater 
experience will retain face value forever unless the 
current paradigm is questioned. So, we hope that in the 
near future the clinician will be provided with data 
regarding the use of the newer biologics as ﬁ  rst line and 
we can progress to a more evidence-based selection 
among these agents.
Last but not least, the costs of each must be taken into 
account while choosing the optimal biological treatment. 
Costs vary among countries and cannot be easily 
compared. However, the clinician should keep them in 
mind, and in the absence of other signiﬁ  cant diﬀ  erences 
in beneﬁ  t and risks between various treatment options, 
cost considerations may inﬂ  uence therapeutic choices.
Th   ere are still several unmet needs in RA. Th  e  search 
for valid and reliable biological and clinical markers to 
predict responsiveness to a particular targeted therapy 
and optimize treatment success for a particular individual 
must continue. Th  e ideal sequence of use of biologics 
cannot be clearly established on the basis of available 
data, but the strategy cannot be based solely on issues of 
historical opportunity: the main reason why anti-TNFs 
are considered ﬁ   rst line is that they were the ﬁ  rst  to 
appear. Dynamic treatment strategies avoiding treatment 
delay should be compared, with newer biologics started 
early in the disease course. Switching and rotating among 
biologics until the best possible option is established for 
each individual will allow the accumulation of data on 
their respective eﬃ   cacies and facilitate crucial studies on 
predictors of response.
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